Alpelisib vs Inavolisib: How to Choose Between Two PI3Kα Inhibitors in PIK3CA-Mutated Breast Cancer

　　In hormone receptor(HR)-positive,human epidermal growth factor receptor 2(HER2)-negative advanced or metastatic breast cancer,activating mutations in the PIK3CA gene represent one of the most prevalent driver alterations,occurring in approximately 40%of cases.PIK3CA encodes p110α,the catalytic subunit of phosphoinositide 3-kinase(PI3K),and its mutation leads to constitutive activation of the PI3K/AKT/mTOR signaling pathway,which not only promotes tumor proliferation but also contributes to the development of endocrine therapy resistance.Two PI3Kα-specific inhibitors—alpelisib(brand name Piqray)and inavolisib(brand name Itovebi)—have been approved to target this pathway,forming the core of precision therapy for PIK3CA-mutated breast cancer.

　　Patients and caregivers frequently ask:"Which of these two drugs works better?"Objectively,this question cannot be answered simplistically.To date,no head-to-head clinical trial has directly compared alpelisib with inavolisib,and the two agents were approved based on studies with different designs and patient populations.The more rational approach is therefore not to rank the drugs by intrinsic"strength,"but to individualize selection based on treatment line,prior endocrine therapy history,PIK3CA mutation status,and the evidence base of each combination regimen.

　　Alpelisib:The First-Approved,Mature PIK3CA-Targeted Option.Alpelisib was the world's first PI3Kα-specific inhibitor approved for breast cancer.In May 2019,the U.S.Food and Drug Administration(FDA)approved alpelisib in combination with fulvestrant for postmenopausal women and men with HR-positive,HER2-negative,PIK3CA-mutated advanced or metastatic breast cancer—as detected by an FDA-approved test—who experienced disease progression on or after endocrine therapy.The companion therascreen PIK3CA RGQ PCR Kit was simultaneously approved for detecting PIK3CA mutations in tissue or liquid biopsy specimens.

　　The approval was based on the landmark phase 3 SOLAR-1 trial,a multicenter,randomized,double-blind,placebo-controlled study that enrolled 572 patients with HR-positive,HER2-negative advanced breast cancer,of whom 341 had confirmed PIK3CA-activating mutations.In the PIK3CA-mutated cohort,alpelisib plus fulvestrant nearly doubled median progression-free survival compared with fulvestrant alone(approximately 11.0 vs.5.7 months),with a substantially higher objective response rate(26.6%vs.12.8%).SOLAR-1 was the first large-scale study to demonstrate a clear survival benefit of PI3K inhibition in PIK3CA-mutated breast cancer,establishing alpelisib as a standard second-line option following progression on endocrine therapy.

　　Inavolisib:A Next-Generation Agent Featuring Mutant Degradation and a Triplet Regimen.Inavolisib is also a highly selective PI3Kαinhibitor,but its molecular design is distinctive.Beyond potently inhibiting mutant PI3Kαkinase activity,inavolisib specifically triggers the degradation of mutant PI3Kαprotein,theoretically enabling deeper and more durable pathway suppression while exerting relatively less impact on wild-type PI3Kα—an attribute that may improve metabolic tolerability.This profile earned inavolisib FDA Breakthrough Therapy designation prior to approval.

　　On October 10,2024,the FDA approved inavolisib in combination with the CDK4/6 inhibitor palbociclib and fulvestrant for adults with endocrine-resistant,PIK3CA-mutated,HR-positive,HER2-negative locally advanced or metastatic breast cancer who experienced disease recurrence during or after adjuvant endocrine therapy.Unlike alpelisib's two-drug regimen,inavolisib was approved from the outset as a triplet—"PI3Kαinhibitor plus CDK4/6 inhibitor plus endocrine therapy"—a distinguishing feature of its approved indication.

　　The approval was supported by the phase 3 INAVO120 trial(NCT04191499),a randomized,double-blind,placebo-controlled study enrolling 325 patients with PIK3CA-mutated,HR-positive,HER2-negative locally advanced or metastatic breast cancer who had relapsed during or within 12 months of completing adjuvant endocrine therapy and had received no prior CDK4/6 inhibitor.Adding inavolisib to palbociclib and fulvestrant reduced the risk of disease progression or death by 57%versus placebo plus palbociclib and fulvestrant(HR 0.43;95%CI:0.32–0.59;P<0.0001),with median PFS of approximately 15.0 versus 7.3 months.Initial results were presented at the 2023 San Antonio Breast Cancer Symposium,expanded data were disclosed at the 2024 ASCO Annual Meeting,and full efficacy and safety results were published in The New England Journal of Medicine.Subsequent analyses further demonstrated a statistically significant overall survival(OS)improvement with the inavolisib triplet,strengthening the totality of evidence.

　　How to Choose?The Key Lies in Treatment Stage and Prior Therapy.Because the approved indications of the two drugs do not fully overlap,the core logic of clinical selection centers on"where the patient stands in the treatment journey."

　　For patients who have received prior endocrine therapy(with or without a CDK4/6 inhibitor)and subsequently progressed,with a confirmed PIK3CA mutation,alpelisib plus fulvestrant represents a well-established second-line standard with a long track record of clinical evidence and real-world experience.

　　For the specific population exhibiting endocrine resistance with recurrence during or shortly after adjuvant endocrine therapy,and no prior CDK4/6 inhibitor exposure in the advanced setting,the inavolisib-palbociclib-fulvestrant triplet offers the most contemporary evidence base,including near-doubling of PFS and a significant OS benefit,making it a compelling option for this scenario.

　　It must be emphasized that INAVO120 and SOLAR-1 differed in enrolled populations,control arms,and treatment lines;their data cannot be directly compared across studies.Drug selection should therefore not be driven by numerical comparisons between trials,but rather by individualized assessment conducted by specialists experienced in precision breast cancer therapy.

　　Safety Profiles:Shared Hyperglycemia Concerns,Different Management Contexts.As fellow PI3Kαinhibitors,alpelisib and inavolisib share common adverse-event features.Hyperglycemia is an on-mechanism toxicity of PI3Kαinhibition(since PI3Kαmediates insulin signaling)and can occur with both agents.It is typically managed through dietary modification,prophylactic oral antihyperglycemic agents such as metformin,and regular monitoring of fasting glucose and HbA1c.Both drugs may also cause diarrhea and rash;rash tends to be more frequent with alpelisib(prophylactic antihistamines may be considered),while stomatitis is more commonly observed with inavolisib.

　　Importantly,inavolisib is not used as monotherapy but as part of a triplet regimen with palbociclib and fulvestrant.Consequently,tolerability assessment must also account for CDK4/6 inhibitor-related adverse events such as neutropenia,and the overall safety evaluation should encompass all three agents.For patients with poorly controlled baseline glucose,a history of diabetes,or multiple comorbidities,the hyperglycemia risk should be carefully weighed before drug selection,with a detailed monitoring and intervention plan established prior to treatment initiation.

　　A Rational Perspective:Not"Better,"but"Better Suited."In summary,alpelisib and inavolisib represent two developmental stages of precision therapy for PIK3CA-mutated breast cancer.Alpelisib is the pioneering,mature option with long-accumulated evidence in the post-endocrine-progression setting.Inavolisib,characterized by its mutant-degradation mechanism and triplet design,delivers more recent and robust data in the endocrine-resistant,post-adjuvant recurrence population.The two agents are not simple substitutes for one another;they serve distinct patient populations in different therapeutic contexts.

　　The final treatment decision should rest on the following foundations:validated PIK3CA mutation testing(tissue or liquid biopsy),a comprehensive review of prior treatment history,assessment of the timing and pattern of disease progression,evaluation of tolerability to adverse events such as hyperglycemia,and the patient's own treatment preferences.Within a multidisciplinary and individualized framework,every patient with PIK3CA-mutated breast cancer can identify the precision therapy pathway best suited to their situation.